Manatt’s Adam Finkelstein, a counsel with our Manatt Health group, was interviewed by Healthcare Financial Management to discuss Medicare’s expansion of its value-based insurance design (VBID) model and its plans to create a new drug plan model.
The publication noted that the VBID expansion will allow the Centers for Medicare & Medicaid Services (CMS) to test new developments in the Medicare Advantage program. Additionally, a separate Part D model will test whether plans can minimize Medicare drug spending.
“I think both models are good ideas that hold a lot of potential,” said Finkelstein. “The details of each model’s implementation really matter, though, and it is hard to gauge the prospects of success without seeing how CMS plans to implement them in practice.”
Read the article here.